Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Chlamydia trachomatis | dihydrolipoyl dehydrogenase | 0.0072 | 0.026 | 0.5 |
Echinococcus multilocularis | thioredoxin glutathione reductase | 0.0207 | 1 | 1 |
Mycobacterium leprae | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE | 0.0072 | 0.026 | 0.5 |
Mycobacterium ulcerans | flavoprotein disulfide reductase | 0.0072 | 0.026 | 0.5 |
Toxoplasma gondii | thioredoxin reductase | 0.0207 | 1 | 1 |
Leishmania major | trypanothione reductase | 0.0207 | 1 | 1 |
Plasmodium falciparum | thioredoxin reductase | 0.0207 | 1 | 1 |
Echinococcus granulosus | ryanodine receptor 44f | 0.0088 | 0.1416 | 0.1416 |
Trypanosoma brucei | trypanothione reductase | 0.0207 | 1 | 1 |
Schistosoma mansoni | inositol 145-trisphosphate receptor | 0.0153 | 0.609 | 0.5985 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase | 0.0072 | 0.026 | 0.5 |
Brugia malayi | Thioredoxin reductase | 0.0207 | 1 | 1 |
Loa Loa (eye worm) | thioredoxin reductase | 0.0207 | 1 | 1 |
Trypanosoma cruzi | trypanothione reductase, putative | 0.0207 | 1 | 1 |
Loa Loa (eye worm) | glutathione reductase | 0.0207 | 1 | 1 |
Echinococcus granulosus | thioredoxin glutathione reductase | 0.0207 | 1 | 1 |
Plasmodium vivax | glutathione reductase, putative | 0.0207 | 1 | 1 |
Echinococcus granulosus | dihydrolipoamide dehydrogenase | 0.0072 | 0.026 | 0.026 |
Trichomonas vaginalis | glutathione reductase, putative | 0.0072 | 0.026 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0117 | 0.354 | 0.2475 |
Leishmania major | dihydrolipoamide dehydrogenase, putative | 0.0072 | 0.026 | 0.0099 |
Plasmodium vivax | thioredoxin reductase, putative | 0.0207 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.01 | 0.2287 | 0.1015 |
Mycobacterium tuberculosis | NADPH-dependent mycothiol reductase Mtr | 0.0207 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0072 | 0.026 | 0.5 |
Schistosoma mansoni | inositol 145-trisphosphate receptor | 0.01 | 0.2287 | 0.2081 |
Leishmania major | acetoin dehydrogenase e3 component-like protein | 0.0072 | 0.026 | 0.0099 |
Leishmania major | 2-oxoglutarate dehydrogenase, e3 component, lipoamidedehydrogenase-like protein | 0.0072 | 0.026 | 0.0099 |
Trichomonas vaginalis | mercuric reductase, putative | 0.0072 | 0.026 | 0.5 |
Giardia lamblia | NADH oxidase lateral transfer candidate | 0.0072 | 0.026 | 0.5 |
Leishmania major | dihydrolipoamide dehydrogenase, putative | 0.0072 | 0.026 | 0.0099 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase, LpdB | 0.0072 | 0.026 | 0.5 |
Treponema pallidum | NADH oxidase | 0.0072 | 0.026 | 0.5 |
Trypanosoma cruzi | inositol 1,4,5-trisphosphate receptor, putative | 0.0103 | 0.2549 | 0.235 |
Plasmodium falciparum | glutathione reductase | 0.0207 | 1 | 1 |
Brugia malayi | cation channel family protein | 0.0188 | 0.8608 | 0.8571 |
Echinococcus multilocularis | ryanodine receptor 44f | 0.0088 | 0.1416 | 0.1416 |
Schistosoma mansoni | ryanodine receptor related | 0.0123 | 0.3934 | 0.3772 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0072 | 0.026 | 0.5 |
Brugia malayi | Ryanodine Receptor TM 4-6 family protein | 0.0123 | 0.3934 | 0.3772 |
Trypanosoma brucei | inositol 1,4,5-trisphosphate receptor | 0.0103 | 0.2549 | 0.235 |
Loa Loa (eye worm) | hypothetical protein | 0.0119 | 0.3703 | 0.2664 |
Echinococcus multilocularis | dihydrolipoamide dehydrogenase | 0.0072 | 0.026 | 0.026 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED20 (functional) | = 0.024 mM kg-1 | Hypoglycemic activity by lowering blood glucose in normal rats by 20% after oral administration. | ChEMBL. | 6864736 |
ED50 (functional) | = 0.062 mM kg-1 | Hypoglycemic activity by lowering blood glucose in normal rats by 50% after oral administration. | ChEMBL. | 6864736 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.